L'intérêt à découvert pour Neurocrine Biosciences donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Neurocrine Biosciences. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Neurocrine Biosciences (NASDAQ:NBIX) Stock, Rapport sur les intérêts à découvert

Neurocrine Biosciences

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences Inc

NEUROCRINE BIOSCIENCES ORD

A substantial insider activity was disclosed on November 12, as ROBERTS, Chief Medical Officer at Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>), reported the exercise of a large sell of company stock options.
What Happened: A notable Form 4 filing on Tuesday with the <a href="https://www.sec.gov/Archives/edgar/data/0000914475/000091447524000220//Archives/edgar/data/914475/000091447524000220/0000914475-24-000220-index.htm">U.S. Securities and Exchange Commission</a> revealed that ROBERTS, Chief Medical Officer at Neurocrine Biosciences, exercised stock options for 7,345 shares of NBIX, resulting in a transaction value of $334,925.
Neurocrine Biosciences shares are trading, exhibiting up of 0.2% and priced at $127.27 during Wednesday's morning. This values ROBERTS's 7,345 shares at $334,925.
<h3>Discovering Neurocrine Biosciences: A Closer Look</h3>
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
<h3>Neurocrine Biosciences's Economic Impact: An Analysis</h3>
Revenue Growth: Neurocrine Biosciences displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 24.72%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 98.71%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Neurocrine Biosciences exhibits below-average bottom-line performance with a current EPS of 1.28.
</li>
</ul>
Debt Management: Neurocrine Biosciences's debt-to-equity ratio is below the industry average. With a ratio of 0.09, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Insights into Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 33.88 is lower than the industry average, implying a discounted valuation for Neurocrine Biosciences's stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 5.87 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Neurocrine Biosciences's EV/EBITDA ratio, surpassing industry averages at 21.38, positions it with an above-average valuation in the market.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Unmasking the Significance of Insider Transactions</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Transaction Codes Worth Your Attention</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000914475">Check Out The Full List Of Neurocrine Biosciences's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Insider Trades

Trading Ideas

NBIX

Strategic Sale: EIRY ROBERTS Decides To Exercise Options Worth $334K At Neurocrine Biosciences

On Monday,&nbsp;AbbVie&nbsp;Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41884798/abbvies-emraclidine-for-schizophrenia-surprisingly-disappoints-analyst-says-pipeline-is-underappreciated" rel="noreferrer noopener">two Phase 2 trials</a>.
The studies did not meet their primary endpoint of showing a statistically significant improvement in the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score compared to the placebo group at week 6.
Truist says due to the failure, Bristol Myers Squibb&nbsp;&amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Cobenfy (xanomeline and trospium chloride, KarXT) is poised to have less commercial competition.
The analyst also adds that the update will likely raise questions about strategy in neuroscience for AbbVie, which was highlighted during their <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41626490/abbvie-tops-q3-expectations-as-skyrizi-rinvoq-drive-growth" rel="noreferrer noopener">third-quarter earnings call</a>.
The analyst, with a Buy rating and $215 price target, is still positive on AbbVie&#8217;s growth prospects particularly from their immunology I&amp;I franchise.
Emraclidine was part of AbbVie&#8217;s acquisition of Cerevel last year, which also included Tavapadon, which recently reported positive Phase 3 results in Parkinson&#8217;s disease.
The trial met its primary endpoint – patients treated with tavapadon in both dose groups experienced a statistically significant reduction (improvement) from baseline compared to placebo (placebo: +1.8; 5 mg: -9.7; 15 mg: -10.2 versus placebo) in the Movement Disorder Society – Unified Parkinson&#8217;s Disease Rating Scale (MDS-UPDRS) Parts II and III <a href="https://www.benzinga.com/general/biotech/24/09/41050209/abbvie-says-pivotal-trial-for-parkinsons-candidate-meets-its-primary-goal-in-patients-with-early-" target="_blank" rel="noreferrer noopener">combined score at week 26</a>.
Also Read: <a href="https://www.benzinga.com//node/41884798">AbbVie&#8217;s Emraclidine For Schizophrenia &#8216;Surprisingly Disappoints,&#8217; Analyst Says Pipeline Is Underappreciated</a>
BMO Capital Markets writes, &#8220;AbbVie core I&amp;I thesis intact, but this one stings.&#8221;
The analyst has lowered the <a target="_blank" href="https://www.benzinga.com/quote/ABBV/analyst-ratings" rel="noreferrer noopener">price target from $228</a> to $208 and maintains the Outperform rating, citing confidence in the immunology portfolio.
BMO analyst writes that While Neurocrine Biosciences Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) mixed phase 2 data from NBI-1117568 <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40632561/neurocrine-biosciences-lower-dose-data-puts-its-schizophrenia-candidate-in-the-game" rel="noreferrer noopener">showed some efficacy</a>, there was absolutely no benefit in these trials. Bristol&#8217;s Cobenfy is now poised to dominate the schizophrenia market, the analyst adds.
BMO has reduced the probability of success for emraclidine to 0%, which was previously estimated to reach a potential $3.9 billion in global unadjusted peak sales in the Schizophrenia indication.
Price Action: ABBV stock is down 0.84% at $172.96 at last check Tuesday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/41913107">Bristol-Myers Squibb&#8217;s $14 Billion Potential &#8211; Analyst Upgrades Stock</a></li>
</ul>

Analyst Color

Biotech

Equities

Large Cap

Health Care

Price Target

Reiteration

Analyst Ratings

General

ABBV

AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio

Needham analyst Ami Fadia reiterates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Hold.

Needham Reiterates Hold on Neurocrine Biosciences

Neurocrine Biosciences Unveils KINECT-HD Data Demonstrating Consistent Efficacy Of INGREZZA In Huntington's Disease Chorea Across 19 Subgroups, Showing Positive Impact On Emotional Health

Neurocrine Biosciences Reveals New INGREZZA Data At Psych Congress 2024, Showing 60% Remission Rate For Tardive Dyskinesia After 48 Weeks In Long-Term Study

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and maintains $190 price target.

HC Wainwright & Co. Reiterates Buy on Neurocrine Biosciences, Maintains $190 Price Target

WIIM

Neurocrine Biosciences shares are trading higher after the company reported better-than-expected Q3 financial results and raised annual valbenazine revenue outlook. It also authorized $300 million stock buyback.

Guidance

Neurocrine Biosciences Raises FY24 Net Product (valbenazine) Revenue Outlook To $2.30B-$2.32B

Announced the Company's Board of Directors has authorized a $300 million share repurchase plan. The Company subsequently intends to enter into a $300 million accelerated share repurchase transaction in the coming days, subject to market conditions, which will constitute the entirety of the authorized share repurchase plan.

Buybacks

Neurocrine Biosciences Board Authorizes $300M Stock Buyback

Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) reported quarterly earnings of $1.81 per share which beat the analyst consensus estimate of $1.51 by 19.87 percent. This is a 17.53 percent increase over earnings of $1.54 per share from the same period last year. The company reported quarterly sales of $622.100 million which beat the analyst consensus estimate of $600.628 million by 3.57 percent. This is a 24.72 percent increase over sales of $498.800 million the same period last year.

Earnings

Earnings Beats

Neurocrine Biosciences Q3 2024 Adj. EPS $1.81 Beats $1.51 Estimate, Sales $622.100M Beat $600.628M Estimate

Providing a diverse range of perspectives from bullish to bearish, 20 analysts have published ratings on Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $161.9, with a high estimate of $219.00 and a low estimate of $114.00. This current average reflects an increase of 1.99% from the previous average price target of $158.74. 
<img src="https://www.benzinga.com/files/images/story/2024/1730203251_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Neurocrine Biosciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$114.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Danielle Brill</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$155.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$133.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$128.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$159.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$136.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Akash Tewari</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$189.00</td>
<td>$177.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$181.00</td>
<td>$173.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$143.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$158.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$219.00</td>
<td>$216.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$180.00</td>
<td>$157.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Neurocrine Biosciences. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Neurocrine Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Neurocrine Biosciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Neurocrine Biosciences's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/NBIX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Neurocrine Biosciences analyst ratings.</a>
<h2>Get to Know Neurocrine Biosciences Better</h2>
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
<h3>Understanding the Numbers: Neurocrine Biosciences's Finances</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Neurocrine Biosciences's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 30.37%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Neurocrine Biosciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 11.01%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Neurocrine Biosciences's ROE stands out, surpassing industry averages. With an impressive ROE of 2.66%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Neurocrine Biosciences's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.92% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Neurocrine Biosciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.1.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Examination Of 20 Analyst Recommendations For Neurocrine Biosciences

BMO Capital analyst Evan Seigerman maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Market Perform and lowers the price target from $128 to $114.

BMO Capital Maintains Market Perform on Neurocrine Biosciences, Lowers Price Target to $114

Raymond James analyst Danielle Brill reinstates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Outperform and announces $155 price target.

Initiation

Raymond James Reinstates Outperform on Neurocrine Biosciences, Announces $155 Price Target

RBC Capital analyst Brian Abrahams reiterates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Sector Perform and maintains $133 price target.

RBC Capital Reiterates Sector Perform on Neurocrine Biosciences, Maintains $133 Price Target

During the last three months, 20 analysts shared their evaluations of Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">11</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $166.7, along with a high estimate of $219.00 and a low estimate of $128.00. This upward trend is evident, with the current average reflecting a 2.93% increase from the previous average price target of $161.95.
<img src="https://www.benzinga.com/files/images/story/2024/1728057676_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Neurocrine Biosciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$133.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$128.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$159.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$136.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Akash Tewari</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$189.00</td>
<td>$177.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$181.00</td>
<td>$173.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$143.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$158.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$219.00</td>
<td>$216.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$180.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$170.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$173.00</td>
<td>$169.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Neurocrine Biosciences. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Neurocrine Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Neurocrine Biosciences's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Neurocrine Biosciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NBIX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Neurocrine Biosciences analyst ratings.</a>
<h2>Discovering Neurocrine Biosciences: A Closer Look</h2>
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
<h3>Neurocrine Biosciences's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Neurocrine Biosciences's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 30.37%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Neurocrine Biosciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 11.01%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Neurocrine Biosciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.66% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Neurocrine Biosciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.92%, the company showcases efficient use of assets and strong financial health.
Debt Management: Neurocrine Biosciences's debt-to-equity ratio is below the industry average. With a ratio of 0.1, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Critical Insights From Neurocrine Biosciences Analyst Ratings: What You Need To Know

RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Sector Perform and lowers the price target from $136 to $133.

RBC Capital Maintains Sector Perform on Neurocrine Biosciences, Lowers Price Target to $133

Neurocrine Biosciences Highlights Presentation Of Interim Data Showing Robust And Sustained Improvements In Chorea Associated With Huntington's Disease Through Week 104 Irrespective Of Antipsychotic Use

Needham analyst Ami Fadia has maintained their neutral stance on NBIX stock, giving a Hold rating on October 31. Ami Fadia's rating is based on sev...

Neurocrine Biosciences: Balancing Strategic Priorities with Regulatory Challenges – Analyst Maintains Hold Rating

Why Neurocrine Biosciences Stock Is Very Attractive At Current Levels

Evercore ISI argues that the "very surprising negative pivotal results" from AbbVie's (ABBV) emraclidine EMPOWER trials "will be felt across the mu...

Evercore says failure of emraclidine 'may' be 'substantial' Neurocrine positive

Analyst Cory Kasimov of Evercore ISI maintained a Buy rating on Neurocrine (NBIX – Research Report), retaining the price target of $175.00. Cory Ka...

Buy Rating for Neurocrine: Strategic Advantage Amidst Reduced Competition in Muscarinic Space

AbbVie: Emraclidine's Failure Eliminates An Important Growth Driver

Oppenheimer analyst Jay Olson maintained a Buy rating on Neurocrine (NBIX – Research Report) today and set a price target of $192.00. The company's...

Neurocrine (NBIX) Gets a Buy from Oppenheimer

Jefferies analyst Akash Tewari maintained a Buy rating on Neurocrine (NBIX – Research Report) today and set a price target of $158.00. The company'...

Neurocrine (NBIX) Receives a Buy from Jefferies

Baird Q3 2024 Small/Mid Cap Growth Equity Fund Commentary

Harding Loevner Global Small Companies Equity Q3 2024 Report

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Healthequity (HQY – Research Report) and Neurocrine ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

AAON

ACLS

ALAB

APPF

ATKR

BOOT

BROS

BURL

BWXT

CACI

CASY

CRWKF

CWAN

CYBR

EXLS

FANG

FIVE

FOUR

GWRE

INSP

IRTC

JKHY

KNSL

LGIH

LSCC

MANH

MEDP

MNDY

ONTO

PCOR

PODD

POOL

PRCT

RXST

SITM

SMPL

TARS

TCGGY

TCHBF

TEVA

TEVJF

TREX

VNOM

Press Releases

Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia

Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit

Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results

Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance

Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia

Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules

Neurocrine Biosciences to Participate at Investor Conferences in November

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules

Comments

Neurocrine Biosciences

Intérêt court

Neurocrine Biosciences (NASDAQ:NBIX) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL